Joe has been deeply immersed in the brand packaging and print world for most of his professional career, working for technology leaders like Kodak, HP, Pantone and now ESKO. In his current role as business development manager for brands, Joe partners with the world’s top brands and their key suppliers, to support use of technology and services to drive artwork routing and approval , asset management, and color and packaging process strategy. Joe is based in the Midwestern United States and is an expert baker and amateur small engine mechanic in his spare time.
Mark is a research professional with 25 years in drug development, sales leadership, licensing, and program management. Mark’s experience includes an extensive career at Pfizer in R&D, program leadership at the biotech MannKind Corporation, and stints in sales and sales leadership at IQVIA, Covance, and ICON. Mark joined Medidata through the acquisition of MC10 where he was the VP of Sales. Having earned an honors degree in molecular and cellular from the University of Connecticut, an MBA from Rensselaer Polytechnic Institute, and multiple executive leadership certificates from the Harvard Business School, Mark has been involved in most aspects of drug development throughout his career and is a seasoned corporate leader.
Paul has vast experience in inhaled product development across pharmaceutical and consumer products.
He commenced his career working at a specialty pharmaceutical company where he gained experience of dry powder and metered dose inhaler development including treating local lung conditions and for systemic absorption for all stages of product development and commercial scale up. He also managed and successfully led the Quality Control department in a multinational pharmaceutical company that manufactured generic nicotine lozenges.
Paul led the product characterisation team at Imperial Brands, where he designed the testing strategy for the chemistry of inhaled and oral next generation nicotine products assessing a variety of prototypes at the early stages of development and for regulatory submissions, including PMTA.
He joined Broughton Nicotine Services in 2021 as Head of Scientific Affairs and is responsible for consulting on and developing next generation nicotine product testing strategies for clients.
Shane Smith is the Managing Director of ExtLe (pronounced XTEL) Solutions Limited, a company based in Cambridge in the UK. He has over 35 years of experience in industrial analytical chemistry, with three quarters of that time spent in the pharmaceutical sector. As well as being an expert on extractables and leachables (E&L), he is a specialist in trace analysis and the separation sciences.
From 2004, he worked for GlaxoSmithKline’s world class E&L team at Stevenage in the UK, managing E&L projects for global cross-site project teams. He was ultimately responsibility for the E&L content of successful filings submitted to Regulatory Agencies across the world including North America, Europe, and other territories.
Shane left GlaxoSmithKline in early 2016 to pursue a career as an Independent Consultant and set up ExtLe Solutions to provide specialist E&L consultancy services.
With over 40 years’ combined experience dealing with E&Ls in an ever increasingly complex regulatory environment within the pharmaceutical industry, Shane and the team at ExtLe Solutions are able to apply best practise to vaping and e-liquid products, resulting in robust, scientifically sound E&L strategies for their clients’ products.
Derk Arts MD, PhD has over fifteen years of experience in medicine, research and technology. He founded Castor to solve the biggest issues in clinical research: a lack of inclusivity, patient focus and impact of data. Castor enables sponsors worldwide to run patient-centric trials on a unified platform, that helps them maximize the impact of research data on patient lives.
Dr. Derk Arts believes the key to achieving lasting change in the industry is through scalability and standardization. Technology to run better trials and maximize the impact of data should be available to all researchers.
Over the past 12 months, Castor provided pro-bono support to over 300 COVID-19 trials, and provided the entire infrastructure for the World Health Organizations’ Solidarity Trials.
